» Articles » PMID: 30107991

Rabies Vaccines: WHO Position Paper, April 2018 - Recommendations

Overview
Journal Vaccine
Date 2018 Aug 16
PMID 30107991
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

This article presented the World Health Organization's (WHO) recommendations on the use of Rabies vaccines excerpted from the Rabies vaccines: WHO position paper - April 2018 published in the Weekly Epidemiological Record [1] This position paper replaces the 2010 WHO position paper on rabies vaccines [2]. It presents new evidence in the field of rabies and the use of rabies vaccines, focussing on programmatic feasibility, simplification of vaccination schedules and improved cost-effectiveness. The recommendations concern the 2 main immunization strategies, namely vaccination for post-exposure prophylaxis and vaccination for pre-exposure prophylaxis. In the context of post-exposure prophylaxis, recommendations are also provided on the use of rabies immunoglobulins. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation tables. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of cholera vaccines were discussed by the Strategic Advisory Group of Experts (SAGE) in October 2017; evidence presented at these meetings can be accessed at: http://www.who.int/immunization/sage/meetings/2017/october/presentations_background_docs/en/.

Citing Articles

Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination.

Fujisawa M, Onodera T, Kuroda D, Kewcharoenwong C, Sasaki M, Itakura Y NPJ Vaccines. 2025; 10(1):39.

PMID: 39988605 PMC: 11847937. DOI: 10.1038/s41541-025-01073-5.


Documenting challenges in achieving rabies elimination by 2030 in low-middle income countries; a Kenyan case study from Lamu County, 2020-2022: mixed methods approach.

Mwanyalu N, Mwatondo A, Chuchu V, Maina K, Muturi M, Mutiiria M One Health Outlook. 2025; 7(1):6.

PMID: 39924474 PMC: 11809077. DOI: 10.1186/s42522-024-00129-1.


Mass rabies exposure of veterinary health care workers in Germany: Management, immune response, and tolerability of post exposure-prophylaxis.

Lemmermann L, Remppis J, Belard S, Steiner F One Health. 2025; 20:100978.

PMID: 39911941 PMC: 11795150. DOI: 10.1016/j.onehlt.2025.100978.


The Deadly Details: How Clear and Complete Are Publicly Available Sources of Human Rabies Information?.

Patane N, Eades O, Morris J, Mac O, McCaffery K, McGuinness S Trop Med Infect Dis. 2025; 10(1).

PMID: 39852667 PMC: 11768519. DOI: 10.3390/tropicalmed10010016.


Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.

Aditham A, Radford C, Carr C, Jasti N, King N, Bloom J bioRxiv. 2025; .

PMID: 39763725 PMC: 11702696. DOI: 10.1101/2024.12.17.628970.